KYinno secures nearly RMB 35M Series B for bispecific/multispecific antibody discovery
On December 15, KYinno, a biotechnology company focused on the research and development of next-generation bispecific and multispecific antibody drugs, announced the successful completion of its Series B financing round, raising nearly RMB 250 million. This round was jointly led by BioTrack Capital, Beijing Pharmaceutical and Healthcare Industry Investment Fund, and E-Town Capital, with follow-on investments from Everbright Limited, Jinyi Fuxin, Renai Capital, and Yizhuang Investment. Existing shareholder Yuanhui Chuangyi continued to invest additional capital.
It is reported that the funds raised in this round will primarily be used to accelerate the collaborative development and clinical advancement of several First-in-Class (FIC) and Best-in-Class (BIC) bispecific/multispecific antibody drugs under KYinno's pipeline, further strengthen its proprietary Common Light Chain and Heavy Chain Nanobody Technology Platform, and actively expand global licensing partnerships.
KYinno is a biotechnology company focused on the research and development of next-generation bispecific and multispecific antibody therapeutics. Building on its proprietary technology platforms — the Common Light Chain Platform and the Heavy Chain Nanobody Platform — the company is committed to developing globally competitive First-in-Class and Best-in-Class innovative drugs targeting therapeutic areas including oncology and autoimmune diseases. Furthermore, KYinno aims to empower global pharmaceutical innovation through its distinctive technology platforms.
1Deeply Cultivating in the Bispecific/Multi-Specific Antibody Field, Two Core Platforms Build Technical Barriers
As an innovation-driven biotech company, KYinno has focused on the drug discovery phase since its establishment in 2017. It has developed the industry's largest gene-edited cell bank, a common light chain mouse platform, a nanobody platform, and related validation systems. Through breakthroughs in antibody discovery technology, the company addresses critical industry challenges in traditional bispecific antibody development, such as low discovery efficiency, heavy-light chain mispairing, poor druggability, and complex manufacturing processes. The combined application of its "common light chain" and "Heavy Chain" nanobody technology platform has also significantly expanded its combinatorial possibilities and design capabilities in multispecific antibodies.
The success of this financing round stems from investors' strong recognition of the value of KYinno's two core technology platforms.
One major challenge in bispecific antibody development is screening efficiency. KYinno has designed proprietary light chain sequences based on AI and bioinformatics technology, which significantly improve compatibility with heavy chains and ensure the identification of bispecific antibody molecules that meet desired molecular characteristics. The second key challenge is solving heavy-light chain mispairing. KYinno's common light chain technology fundamentally eliminates light chain mispairing, greatly simplifying the Chemistry, Manufacturing, and Controls (CMC) process development. Moreover, AI-assisted design substantially enhances the assembly efficiency and stability of bispecific antibody molecules, laying a solid foundation for developing First-in-Class (FIC) bispecific and multispecific antibodies with high druggability.
Leveraging its genetically engineered mouse platform, KYinno can efficiently screen for nanobodies with unique epitope-binding capabilities and excellent tissue penetration. Combined with KYinno's well-established alpaca nanobody development technology, this approach ensures a high success rate in developing nanobodies against target antigens. This platform complements KYinno's common light chain mouse antibody technology, demonstrating highly competitive and differentiated advantages—particularly in constructing multispecific antibodies targeting complex antigens or designed with multivalent architectures to enhance pharmacological efficacy.
2Flexible Business Model, Building a Distinctive Pipeline Portfolio
Building on the aforementioned platforms and through diversified business models including co-development, licensing, out-licensing, and early-stage proprietary projects, KYinno has established a highly differentiated product pipeline. Currently, its core product, the BCMA-GPRC5D-CD3 trispecific antibody (KA001/BMS314) targeting heavily pretreated multiple myeloma, has entered Phase I clinical trials, with multiple dose groups / the RP2D dose group achieving a 100% Overall Response Rate (ORR). Additionally, several bispecific antibody-drug conjugates (ADCs) and bispecific antibody candidates for oncology and autoimmune diseases are in critical stages ranging from candidate nomination (PCC) to Investigational New Drug (IND) application submission.
3Focusing on Early Drug Discovery, Building Multiple Validation Platforms to Empower Global Pharmaceutical R&D
KYinno has established an integrated technology platform covering critical early-stage drug discovery processes, ranging from the construction of gene-edited cellular models to antibody discovery and AI-assisted design, and further to in vitro and in vivo efficacy evaluation. This platform empowers companies to respond more agilely to R&D trends. Concurrently, KYinno fosters in-depth and flexible strategic partnerships with its clients to promote mutual growth.